Abbott Laboratories
ABT
$133.58
-$0.36-0.27%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.00% | 4.59% | 3.15% | 1.24% | -2.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.00% | 4.59% | 3.15% | 1.24% | -2.84% |
| Cost of Revenue | 3.30% | 4.11% | 1.29% | 0.64% | -2.04% |
| Gross Profit | 6.38% | 4.98% | 4.66% | 1.73% | -3.48% |
| SG&A Expenses | 5.89% | 7.02% | 3.06% | 1.29% | -0.82% |
| Depreciation & Amortization | -6.21% | -4.48% | -4.39% | -3.18% | -2.26% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.89% | 4.81% | 1.50% | 0.20% | -1.65% |
| Operating Income | 10.21% | 3.59% | 11.15% | 6.25% | -8.05% |
| Income Before Tax | 12.50% | 5.24% | 9.52% | 3.71% | -6.49% |
| Income Tax Expenses | -776.98% | -778.96% | -1.56% | -14.62% | -23.57% |
| Earnings from Continuing Operations | 139.82% | 134.18% | 11.72% | 7.67% | -3.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 139.82% | 134.18% | 11.72% | 7.67% | -3.00% |
| EBIT | 10.21% | 3.59% | 11.15% | 6.25% | -8.05% |
| EBITDA | 6.31% | 2.24% | 7.44% | 4.45% | -5.74% |
| EPS Basic | 139.77% | 134.13% | 11.77% | 7.99% | -2.70% |
| Normalized Basic EPS | 10.33% | 2.85% | 10.17% | 4.92% | -7.82% |
| EPS Diluted | 140.08% | 134.55% | 11.93% | 8.21% | -2.38% |
| Normalized Diluted EPS | 10.34% | 2.88% | 10.22% | 4.97% | -7.61% |
| Average Basic Shares Outstanding | -0.02% | -0.03% | -0.08% | -0.30% | -0.37% |
| Average Diluted Shares Outstanding | -0.06% | -0.05% | -0.11% | -0.32% | -0.55% |
| Dividend Per Share | 7.55% | 7.69% | 7.84% | 8.00% | 8.16% |
| Payout Ratio | -0.55% | -0.54% | -0.03% | 0.00% | 0.11% |